TWi Biotech. Business Summary

TWi Biotech (6610.TWO) is a Taiwan-based clinical-stage biopharmaceutical company that operates primarily through a drug repurposing business model, utilizing the US FDA’s 505(b)(2) regulatory pathway to address unmet medical needs. The company generates revenue through strategic licensing agreements, milestone payments, and contract research fees, notably partnering with entities such as Castle Creek Biosciences, R-Pharm, and various international conglomerates. Following its landmark merger with Dukang Pharmaceuticals in September 2025, the company’s business segments have expanded from a core focus on rare dermatological diseases—headlined by its flagship asset AC-203 for Epidermolysis Bullosa Simplex—into neuropsychiatric and central nervous system (CNS) disorders, including treatments for postpartum depression (NORA520). Within the TPEx-listed biotech sector, TWi Biotech competes directly with firms such as Golden Biotechnology (4132), Senhwa Biosciences (6492), and Taigen Biopharmaceuticals (4157), positioning itself as a specialized developer of high-barrier, low-risk therapeutic alternatives for orphan and high-prevalence inflammatory conditions. The company was founded by Dr. Chih-Ming Chen, a renowned pharmaceutical scientist and serial entrepreneur who also established TWi Pharmaceuticals and serves as the controlling shareholder. The leadership team is currently headed by Chairperson Jessica Wu (Wu Yi-Jun), who brings extensive experience from international investment banking and KGI Securities, and Dr. Chen-En Tsai (Cai Cheng-En), who serves as President and Chief Medical Officer following his tenure as VP of Clinical Development at TaiGen Biotechnology. Technical and research operations are overseen by Shao-Ming Lee, Vice President of Technical Affairs, and Gloria Chen, Vice President of R&D. The board of directors is characterized by its deep integration with the broader TWi group and includes strategic oversight from Dr. Chen, ensuring a unified approach to the company’s expanded global clinical pipeline and capital market strategies.